3. Blagosklonny, M. V. “Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition.” Cell Cycle 5, no. 18 (2006): 2087–2102.
4. Ortman, J., V. Velkoff, and H. Hogan. “An Aging Nation: The Older Population in the United States.” May 2014. Открыто по адресу www.census.gov/prod/2014pubs/p25-1140.pdf.
5. Christensen, K., et al. “Ageing Populations: The Challenges Ahead.” The Lancet 374, no. 9696 (2009): 1196–1208; Drachman, D. A. “Aging of the Brain, Entropy, and Alzheimer Disease.” Neurology 67, no. 8 (2006): 1340–1352; Holroyd, C., C. Cooper, and E. Dennison. “Epidemiology of Osteoporosis.” Best Practice & Research: Clinical Endocrinology & Metabolism 22, no. 5 (2008): 671–685.
6. Nair, S., and J. Ren. “Autophagy and Cardiovascular Aging: Lesson Learned from Rapamycin.” Cell Cycle 11, no. 11 (2012): 2092–2099.
7. Powers, R. W., 3rd, et al. “Extension of Chronological Life Span in Yeast by Decreased TOR Pathway Signaling.” Genes & Development 20, no. 2 (2006): 174–184.
8. Robida-Stubbs, S., et al. “TOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxO.” Cell Metabolism 15, no. 5 (2012): 713–724.
9. Bjedov, I., et al. “Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila Melanogaster.” Cell Metabolism 11, no. 1 (2010): 35–46.
10. Harrison, D., et al. “Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice.” Nature 460 (2009): 392–395.
11. Halford, B. “Rapamycin’s Secrets Unearthed.” Chemical & Engineering News 94, no. 29 (2016): 26–30.
12. Urfer, S. R., et al. “A Randomized Controlled Trial to Establish Effects of Short-Term Rapamycin Treatment in 24 Middle-Aged Companion Dogs.” Geroscience 39, no. 2 (2017): 117–127.
13. Lelegren, M., et al. “Pharmaceutical Inhibition of mTOR in the Common Marmoset: Effect of Rapamycin on Regulators of Proteostasis in a Non-Human Primate.” Pathobiology of Aging & Age Related Diseases 6 (2016): 31793.
14. Spilman, P., et al. “Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-Beta Levels in a Mouse Model of Alzheimer’s Disease.” PLoS One 5, no. 4 (2010): e9979.
15. Majumder, S., et al. “Lifelong Rapamycin Administration Ameliorates Age-Dependent Cognitive Deficits by Reducing IL-1beta and Enhancing NMDA Signaling.” Aging Cell 11, no. 2 (2012): 326–335.
16. Liu, Y., et al. “Rapamycin-Induced Metabolic Defects Are Reversible in Both Lean and Obese Mice.” Aging (Albany NY) 6, no. 9 (2014): 742–754.
17. Kolosova, N. G., et al. “Prevention of Age-Related Macular Degeneration-Like Retinopathy by Rapamycin in Rats.” American Journal of Pathology 181, no. 2 (2012): 472–477.
18. Halloran, J., et al. “Chronic Inhibition of Mammalian Target of Rapamycin by Rapamycin Modulates Cognitive and Non-Cognitive Components of Behavior Throughout Lifespan in Mice.” Neuroscience 223 (2012): 102–113; Tsai, P. T., et al. “Autistic-Like Behaviour and Cerebellar Dysfunction in Purkinje Cell Tsc1 Mutant Mice.” Nature 488, no. 7413 (2012): 647–651; Perl, A. “mTOR Activation is a Biomarker and a Central Pathway to Autoimmune Disorders, Cancer, Obesity, and Aging.” Annals of the New York Academy of Science 1346, no. 1 (2015): 33–44.
19. Mahe, E., et al. “Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy.” Transplantation 79, no. 4 (2005): 476–482; McCormack, F. X., et al. “Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis.” New England Journal of Medicine 364, no. 17 (2011): 1595–1606.
20. Mendelsohn, A. R., and J. W. Larrick. “Dissecting Mammalian Target of Rapamycin to Promote Longevity.” Rejuvenation Research 15, no. 3 (2012): 334–337.
21. Johnston, O., et al. “Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients.” Journal of the American Society of Nephrology 19, no. 7 (2008): 1411–1418.
22. Lamming, D. W. “Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.” Cold Spring Harbor Perspectives in Medicine 6, no. 5 (2016).
23. См. примечание 20 выше.
24. Arriola Apelo, S. I., et al. “Alternative Rapamycin Treatment Regimens Mitigate the Impact of Rapamycin on Glucose Homeostasis and the Immune System.” Aging Cell 15, no. 1 (2016): 28–38.
25. См. примечание 11 выше.
26. Carlson, A. J., and F. Hoelzel. “Growth and Longevity of Rats Fed Omnivorous and Vegetarian Diets.” Journal of Nutrition 34, no. 1 (1947): 81–96.
27. Siri-Tarino, P. W., et al. “Meta-Analysis of Prospective Cohort Studies Evaluating the Association of Saturated Fat with Cardiovascular Disease.” American Journal of Clinical Nutrition 91, no. 3 (2010): 535–546.
28. “Background.” National Cancer Institute Office of Cancer Clinical Proteomics Research. Открыто по адресу at https://proteomics.cancer.gov/proteomics/background.
29. Speakman, J. R., S. E. Mitchell, and M. Mazidi. “Calories or Protein? The Effect of Dietary Restriction on Lifespan in Rodents Is Explained by Calories Alone.” Experimental Gerontology 86 (2016): 28–38.
30. Lee, C., and V. Longo. “Dietary Restriction with and Without Caloric Restriction for Healthy Aging.” F1000Research 5 (2016).
31. Longo, V. D., and L. Fontana. “Calorie Restriction and Cancer Prevention: Metabolic and Molecular Mechanisms.” Trends in Pharmacological Sciences 31, no. 2 (2010): 89–98.
32. Fontana, L., et al. “Long-Term Effects of Calorie or Protein Restriction on Serum IGF-1 and IGFBP-3 Concentration in Humans.” Aging Cell 7, no. 5 (2008): 681–687.
33. Huang, C. H., et al. “EGCG Inhibits Protein Synthesis, Lipogenesis, and Cell Cycle Progression Through Activation of AMPK in p53 Positive and Negative Human Hepatoma Cells.” Molecular Nutrition & Food Research 53, no. 9 (2009): 1156–1165.
34. Pazoki-Toroudi, H., et al. “Targeting mTOR Signaling by Polyphenols: A New Therapeutic Target for Ageing.” Ageing Research Reviews 31 (2016): 55–66.
35. Chiu, C. T., et al. “Hibiscus Sabdariffa Leaf Polyphenolic Extract Induces Human Melanoma Cell Death, Apoptosis, and Autophagy.” Journal of Food Science 80, no. 3 (2015): H649–658; Zhang, L., et al. “Polyphenol-Rich Extract of Pimenta Dioica Berries (Allspice) Kills Breast Cancer Cells by Autophagy and Delays Growth of Triple Negative Breast Cancer in Athymic Mice.” Oncotarget 6, no. 18 (2015): 16379–16395; Syed, D. N., et al. “Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities.” Anti-Cancer Agents in Medicinal Chemistry 13, no. 8 (2013): 1149–1161.
